HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Stuart, W. H. Articles by Vermersch, P. Search for Related Content PubMed PubMed Citation Articles by Stuart, W. H. Articles by Vermersch, P.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Concomitant therapy for multiple sclerosis

From the Peachtree Neurological Clinic (Dr. Stuart), Atlanta, Georgia, and the Department of Neurology (Dr. Vermersch), Hôpital R. Salengro, CHRU of Lille, France.

Address correspondence and reprint requests to Dr. William H. Stuart, Peachtree Neurological Clinic, 3200 Downwood Circle, Suite 550, Atlanta, GA 30327; e-mail: whstuart{at}aol.com

Interferon beta (IFNß) is the first-line treatment for patients diagnosed with multiple sclerosis (MS). In patients with MS who experience breakthrough disease while receiving treatment with IFNß, it is common clinical practice to administer additional therapeutic agents. The rationale for use of concomitant therapies in the long-term management of MS is derived from the heterogeneous and multifactorial etiology of this disease. Agents used concomitantly have the potential to exert synergistic effects and slow the progression of disease in patients who experience breakthrough disease. Concomitant therapies that have been reported in patients with MS are reviewed here.